VIVO - Meridian Bioscience: Remaining Cautious Going Into Q4 Earnings
- Company is hitting it out of the park in its Life Science segment.
- Market has already discounted this as we can see from the technical chart.
- We need to see improvement in Diagnostics soon to keep its present valuation.
For further details see:
Meridian Bioscience: Remaining Cautious Going Into Q4 Earnings